was 100% (n = 25, 95% CI: 88-100). Patients requiring alternative salvage therapies were given novel personalised combinations consisting of bismuth, rifabutin and either tetracycline or furazolidone; the eradication rate for this small group was 90% (n = 10, 95% CI: 57-99).Although the sample size is small, this encouraging analysis indicates that the PARC and PBRC salvage therapies can be confidently prescribed without the expense of standard antimicrobial susceptibility testing. The efficacies of alternative antibiotic combinations with small sample sizes are continuously being monitored in our clinic. It is important to note that antibiotic resistant profiles vary from country to country. As a result, the proposed salvage therapies in our previous publication 2 , PARC and PBRC, are suitable only for countries with low rates of resistance to quinolone and rifabutin.
ACKNOWLEDGEMENTThe authors' declarations of personal and financial interests are unchanged from those in the original article.